Role of B7H4 and CD48 in EAE

B7H4 和 CD48 在 EAE 中的作用

基本信息

  • 批准号:
    6985241
  • 负责人:
  • 金额:
    $ 22.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

The overall goal is to dissect the functional roles of the recently identified B7 family member, B7-H4, and the SLAM family member, CD48 (a CD2 ligand), in regulating organ-specific autoimmune diseases. This focus is driven by recent genetic studies of Multiple Sclerosis and murine type 1 diabetes that have implicated the genetic locus that contains these costimulatory molecules (human or mouse homologues) with disease susceptibility, together with our recent studies that point to important roles for B7-H4 and CD48 in regulating T cell activation and tolerance. To investigate the roles of B7-H4 and CD48-mediated signals in the afferent arm of the response where T cells become activated in the periphery, and in the effector arm, where potentially pathogenic T cells are driven to mediate tissue destruction, we are proposing a multifaceted approach. We will 1)investigate the role of the B7-H4 in regulating T cell tolerance and autoimmunity; 2)analyze the role of CD48 in regulating the induction and effector phases of EAE; and 3)examine the roles of CD48 and B7-H4 in regulating T and B cell tolerance. We have assembled a number of novel tools that will enable us to address these important issues. To dissect the role of B7-H4 in EAE, we have developed B7-H4lg and anti-B7-H4 mAb. We also have available B7-H4-/- mice and are in the process of generating transgenic mice that inducibly express B7-H4. Our CD48-/- mice, and anti-CD48 mAb will serve as definitive tools for examining the role of CD48 during EAE. We will use MOG 35-55 specific TCR transgenic mice to visualize the effects of B7-H4 and CD48 dysregulation on the activation, migration and expansion of naive and activated T cells in vivo, and MOG 35-55 TCR x Th double transgenic mice to analyze the roles of B7-H4 and CD48 in regulating B and T cell tolerance to MOG. Taken together, these studies should lead to insights into how B7-H4 and CD48 costimulatory regulate the responses of self-reactive T cells.
总体目标是剖析最近鉴定的B7家族成员B7-H4和SLAM家族成员CD 48(一种CD 2配体)在调节器官特异性免疫应答中的功能作用。 自身免疫性疾病这一焦点是由最近对多发性硬化症和小鼠1型糖尿病的遗传研究所驱动的,这些研究涉及含有这些具有疾病易感性的共刺激分子(人或小鼠同源物)的遗传基因座,以及我们最近的研究,这些研究指出B7-H4和CD 48在调节T细胞活化和免疫调节中的重要作用。 宽容为了研究B7-H4和CD 48介导的信号在反应的传入臂中的作用,其中T细胞在外周中被激活,并且在效应臂中,潜在的致病性T细胞被驱动以介导组织破坏,我们提出了一种多方面的方法。我们将1)研究B7-H4在调节T细胞耐受和自身免疫中的作用; 2)分析CD 48在调节EAE的诱导期和效应期中的作用;和3)检查CD 48和B7-H4在调节T和B细胞耐受中的作用。我们已经收集了一些新的工具,使我们能够解决这些重要问题。为了分析B7-H4在EAE中的作用,我们开发了B7-H4 lg和抗B7-H4 mAb。我们也 有可用的B7-H4-/-小鼠,并且正在产生可诱导表达B7-H4的转基因小鼠。我们的CD 48-/-小鼠和抗CD 48 mAb将作为确定性工具,用于检查CD 48在EAE期间的作用。我们将使用MOG 35-55特异性TCR转基因小鼠来可视化 B7-H4和CD 48失调对体内初始和活化T细胞的活化、迁移和扩增的影响,以及MOG 35-55 TCR x Th双转基因小鼠,以分析B7-H4和CD 48在调节B和T细胞对MOG耐受中的作用。综上所述,这些研究应该有助于深入了解B7-H4和CD 48共刺激如何调节自身反应性T细胞的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arlene H. Sharpe其他文献

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
B7-CD28/CTLA-4 共刺激途径的复杂性。
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8sup+/sup T cells
肿瘤细胞通过改变 CD8+T 细胞中的丙酮酸利用和琥珀酸盐信号来决定抗肿瘤免疫反应
  • DOI:
    10.1016/j.cmet.2022.06.008
  • 发表时间:
    2022-08-02
  • 期刊:
  • 影响因子:
    30.900
  • 作者:
    Ilaria Elia;Jared H. Rowe;Sheila Johnson;Shakchhi Joshi;Giulia Notarangelo;Kiran Kurmi;Sarah Weiss;Gordon J. Freeman;Arlene H. Sharpe;Marcia C. Haigis
  • 通讯作者:
    Marcia C. Haigis
Age-associated remodeling of T cell immunity and metabolism
T 细胞免疫和代谢的年龄相关重塑
  • DOI:
    10.1016/j.cmet.2022.11.005
  • 发表时间:
    2023-01-03
  • 期刊:
  • 影响因子:
    30.900
  • 作者:
    SeongJun Han;Peter Georgiev;Alison E. Ringel;Arlene H. Sharpe;Marcia C. Haigis
  • 通讯作者:
    Marcia C. Haigis
The B7:CD28 family and friends: Unraveling coinhibitory interactions
B7:CD28 家族及朋友:解开共抑制相互作用
  • DOI:
    10.1016/j.immuni.2024.01.013
  • 发表时间:
    2024-02-13
  • 期刊:
  • 影响因子:
    26.300
  • 作者:
    Kelly P. Burke;Apoorvi Chaudhri;Gordon J. Freeman;Arlene H. Sharpe
  • 通讯作者:
    Arlene H. Sharpe
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
PD-L2 是 PD-1 的第二种配体,可抑制 T 细胞活化
  • DOI:
    10.1038/85330
  • 发表时间:
    2001-03-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary;Madhuri Borde;Irene Chernova;Yoshiko Iwai;Andrew J. Long;Julia A. Brown;Raquel Nunes;Edward A. Greenfield;Karen Bourque;Vassiliki A. Boussiotis;Laura L. Carter;Beatriz M. Carreno;Nelly Malenkovich;Hiroyuki Nishimura;Taku Okazaki;Tasuku Honjo;Arlene H. Sharpe;Gordon J. Freeman
  • 通讯作者:
    Gordon J. Freeman

Arlene H. Sharpe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arlene H. Sharpe', 18)}}的其他基金

Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    10210502
  • 财政年份:
    2020
  • 资助金额:
    $ 22.72万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    10153453
  • 财政年份:
    2018
  • 资助金额:
    $ 22.72万
  • 项目类别:
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
项目2:治疗前、治疗期间以及耐药时的肿瘤和免疫微环境的测量和建模
  • 批准号:
    10343840
  • 财政年份:
    2018
  • 资助金额:
    $ 22.72万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    9906872
  • 财政年份:
    2018
  • 资助金额:
    $ 22.72万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    9576657
  • 财政年份:
    2018
  • 资助金额:
    $ 22.72万
  • 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    10207344
  • 财政年份:
    2017
  • 资助金额:
    $ 22.72万
  • 项目类别:
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
项目 1:通过 CRISPR 筛选发现 CD8 和 CD4 细胞命运和功能的调节因子
  • 批准号:
    10207349
  • 财政年份:
    2017
  • 资助金额:
    $ 22.72万
  • 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    9380804
  • 财政年份:
    2017
  • 资助金额:
    $ 22.72万
  • 项目类别:
Core D: Mouse Perturbation Core
核心 D:鼠标扰动核心
  • 批准号:
    10207348
  • 财政年份:
    2017
  • 资助金额:
    $ 22.72万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10207345
  • 财政年份:
    2017
  • 资助金额:
    $ 22.72万
  • 项目类别:

相似海外基金

Analysis of expression of Cd antigens in retinoblastoma, and its application for disease classification and therapeutic strategy
视网膜母细胞瘤中Cd抗原的表达分析及其在疾病分类和治疗策略中的应用
  • 批准号:
    25670726
  • 财政年份:
    2013
  • 资助金额:
    $ 22.72万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了